Integra LifeSciences to Acquire Acclarent from Johnson & Johnson for $275 Million

Integra LifeSciences, a global leader in medical technology, has entered into a definitive agreement to acquire Acclarent from Johnson & Johnson MedTech. The strategic acquisition, valued at $275 million in cash at closing and an additional $5 million contingent upon the achievement of regulatory milestones, is set to bolster Integra's presence in the ear, nose, and throat (ENT) treatment market.

Acclarent, currently a part of J&J MedTech's Ethicon unit, specializes in innovative solutions for sinus dilation, eustachian tube dilation, and surgical navigation systems. The addition of Acclarent to Integra's portfolio, which already includes the MicroFrance line of ENT instruments, positions the company as a leading provider of ENT products and technologies.

Become a Subscriber

Please purchase a subscription to continue reading this article.

Subscribe Now

Further, Jan De Witte, President and CEO of Integra LifeSciences, expressed enthusiasm about the acquisition, citing the rare opportunity it presents for Integra to become a key player in the ENT segment. He emphasized the alignment of Acclarent's culture of pioneering technologies with Integra's legacy of innovation, aiming to make a profound impact on the future of ENT and neurosurgery.

Acclarent's groundbreaking balloon technologies and surgical navigation systems have garnered significant recognition in the market. The company, based in Irvine, California, generated approximately $110 million in product sales in the United States in 2022. With the acquisition expected to close by the second quarter of 2024, Acclarent will join Integra's Codman Specialty Surgical (CSS) division.

Mike McBreen, President of the CSS division, highlighted the strategic importance of the ENT segment as an anatomical adjacency to neurosurgery. The acquisition opens opportunities for close collaboration between ENT and neurosurgeons, particularly in areas like tumor care using skull base approaches. McBreen emphasized Acclarent's strong commercial capabilities, R&D expertise, advanced portfolio, and deep clinical knowledge as valuable assets for Integra to drive future innovation not only in ENT but also across other CSS technology platforms.

The acquisition reflects Integra LifeSciences' commitment to expanding its capabilities and delivering advanced medical solutions. As the healthcare landscape continues to evolve, strategic moves like the acquisition of Acclarent position Integra as a prominent player in the competitive medical technology sector, offering innovative solutions to healthcare professionals and improving patient outcomes.